Omass Therapeutics Ltd. has identified compounds acting as melanocortin MC2 receptor antagonists reported to be useful for the treatment of congenital adrenal hyperplasia, Cushing syndrome, depression, ectopic ACTH syndrome, polycystic ovary syndrome and septic shock.